Therapeutic advances in pruritus as a model of personalized medicine

Pruritus or itch is a sensation that evolved to protect humans and other vertebrates against environmental irritants, parasitic infestations and disease‐borne insects. However, in the setting of chronic skin inflammation and other medical conditions, pruritus can become pathologic and chronic in nature; indeed, chronic pruritus is defined as itch that persists for greater than 6 weeks and significantly impairs the quality of life of patients. It also poses a major therapeutic challenge. However, recent advances in itch biology have led to the development of novel therapies. This review highlights how new innovations in anti‐pruritic medications are revolutionizing the treatment of chronic pruritus and leading to new paradigms of personalized medicine.

• Publication year

  2025

• Venue

  Journal of the European Academy of Dermatology and Venereology

• Publication date

  2025-11-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/jdv.70169PMID 41222106PMCID PMC12933702
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and Safety of Rilzabrutinib in Patients With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Proof-of-Concept Phase II Clinical Trial.

  2025cited by this paper
• Remibrutinib in Chronic Spontaneous Urticaria.

  2025cited by this paper
• No allergy, but mast cells are involved: MRGPRX2 in chronic inflammatory skin diseases

  2025cited by this paper
• Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis

  2025cited by this paper
• Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.

  2024cited by this paper
• Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials.

  2024cited by this paper
• Efficacy and Safety of Abrocitinib in Prurigo Nodularis and Chronic Pruritus of Unknown Origin

  2024cited by this paper
• Baricitinib for the Treatment of Chronic Pruritus of Unknown Origin

  2024cited by this paper
• Landscape of Prurigo Nodularis Clinical Trials

  2024cited by this paper
• Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.

  2024cited by this paper
• Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials

  2023cited by this paper
• Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.

  2023influential reference
• Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis.

  2023cited by this paper
• IL-31–dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis

  2023cited by this paper
• 396 Rapid, substantial and sustained reduction of itch in adults with atopic dermatitis applying ruxolitinib cream 1.5% (SCRATCH-AD)

  2023cited by this paper
• Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.

  2023cited by this paper
• Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.

  2022cited by this paper
• Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies.

  2022cited by this paper
• The translational revolution of itch.

  2022cited by this paper
• Chronic Itch of Unknown Origin Is Associated With an Enhanced Th2 Skin Immune Profile

  2021cited by this paper
• Treatment of patients with chronic pruritus of unknown origin with dupilumab

  2021cited by this paper
• Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence

  2021cited by this paper
• IL-33 Signaling in Sensory Neurons Promotes Dry Skin Itch.

  2021cited by this paper
• Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

  2021cited by this paper
• Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies.

  2021influential reference
• Treatment of Atopic Dermatitis With Ruxolitinib Cream (JAK1/JAK2 Inhibitor) or Triamcinolone Cream.

  2020cited by this paper
• Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.

  2020influential reference
• A basophil-neuronal axis promotes itch.

  2020cited by this paper
• Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

  2020cited by this paper
• Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.

  2020cited by this paper
• Chronic Pruritus of Unknown Origin (CPUO): Uniform Nomenclature and Diagnosis as a Pathway to Standardized Understanding and Treatment.

  2019cited by this paper
• Chronic Pruritus Responding to Dupilumab—A Case Series

  2019cited by this paper
• Activation of Mast-Cell-Expressed Mas-Related G-Protein-Coupled Receptors Drives Non-histaminergic Itch.

  2019cited by this paper
• Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

  2017cited by this paper
• Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch.

  2017influential reference
• IL-33/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy

  2016cited by this paper
• Immune dysregulation underlies a subset of patients with chronic idiopathic pruritus.

  2016cited by this paper
• Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

  2016influential reference
• Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.

  2016cited by this paper
• Identification of a mast cell specific receptor crucial for pseudo-allergic drug reactions

  2014cited by this paper
• A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1.

  2014cited by this paper
• Omalizumab for the Treatment Of Chronic Idiopathic or Spontaneous Urticaria

  2014cited by this paper
• The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch.

  2013cited by this paper
• Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

  2013cited by this paper
• IL-31-IL-31R Interactions Limit the Magnitude of Th2 Cytokine-Dependent Immunity and Inflammation following Intestinal Helminth Infection1

  2009cited by this paper
• IL-31–IL-31R interactions negatively regulate type 2 inflammation in the lung

  2007cited by this paper
• A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord

  2007cited by this paper
• IL-31: a new link between T cells and pruritus in atopic skin inflammation.

  2006cited by this paper
• Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice

  2004cited by this paper
• Specific C-Receptors for Itch in Human Skin

  1997cited by this paper

• No citing papers are available for this paper.